Regulus Therapeutics Inc. (RGLS) Rating Reiterated by Needham & Company LLC
Regulus Therapeutics Inc. (NASDAQ:RGLS)‘s stock had its “hold” rating reaffirmed by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Tuesday.
The analysts wrote, “Regulus reported 3Q17 financial results last wk and we met w/ mgmt for an update today. Both planned clinical trials of RG-012 in Alport Syndrome pts are now underway and an IND has been submitted for RGLS4326 in Autosomal Dominant Polycystic Kidney Disease. Mgmt has identified male X-linked Alport Syndrome as target pt population for clinical development going forward, due to rapid and homogeneous disease progression. We expect top-line results from 10- patient RG-012 biopsy trial early next yr and from 40-patient RG-012 HERA Phase 2 efficacy trial in early 2019. Maintain HOLD, awaiting more data from lead RG-012 program, but also note encouraging progression of platform/ pipeline behind it.””
A number of other brokerages have also weighed in on RGLS. Zacks Investment Research upgraded Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a research note on Tuesday, October 10th. Chardan Capital lowered Regulus Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 2nd. Finally, Wedbush restated an “ourperform” rating and issued a $4.00 target price on shares of Regulus Therapeutics in a research note on Monday, August 7th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $2.60.
Regulus Therapeutics (NASDAQ:RGLS) opened at $0.90 on Tuesday. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.77 and a quick ratio of 6.77. Regulus Therapeutics has a one year low of $0.79 and a one year high of $3.10.
TRADEMARK VIOLATION WARNING: This news story was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/11/16/regulus-therapeutics-inc-rgls-rating-reiterated-by-needham-company-llc.html.
Several institutional investors and hedge funds have recently bought and sold shares of the company. NEA Management Company LLC purchased a new position in shares of Regulus Therapeutics in the 3rd quarter worth about $13,737,000. FMR LLC boosted its holdings in shares of Regulus Therapeutics by 0.5% in the 2nd quarter. FMR LLC now owns 7,977,349 shares of the biopharmaceutical company’s stock worth $7,862,000 after purchasing an additional 37,489 shares in the last quarter. EcoR1 Capital LLC boosted its holdings in shares of Regulus Therapeutics by 145.6% in the 2nd quarter. EcoR1 Capital LLC now owns 3,709,144 shares of the biopharmaceutical company’s stock worth $3,656,000 after purchasing an additional 2,199,144 shares in the last quarter. South Dakota Investment Council boosted its holdings in shares of Regulus Therapeutics by 37.1% in the 3rd quarter. South Dakota Investment Council now owns 1,820,027 shares of the biopharmaceutical company’s stock worth $2,275,000 after purchasing an additional 492,969 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. purchased a new position in shares of Regulus Therapeutics in the 3rd quarter worth about $750,000. Hedge funds and other institutional investors own 33.45% of the company’s stock.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Receive News & Stock Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related stocks with our FREE daily email newsletter.